| GeneLibs

题目:: CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
作者:: Weischer(Maren),Nordestgaard(Børge G),Pharoah(Paul),Bolla(Manjeet K),Nevanlinna(Heli),Van't Veer(Laura J),Garcia-Closas(Montserrat),Hopper(John L),Hall(Per),Andrulis(Irene L),Devilee(Peter),Fasching(Peter A),Anton-Culver(Hoda),Lambrechts(Diether),Hooning(Maartje),Cox(Angela),Giles(Graham G),Burwinkel(Barbara),Lindblom(Annika),Couch(Fergus J),Mannermaa(Arto),Grenaker Alnæs(Grethe),John(Esther M),Dörk(Thilo),Flyger(Henrik),Dunning(Alison M),Wang(Qin),Muranen(Taru A),van Hien(Richard),Figueroa(Jonine),Southey(Melissa C),Czene(Kamila),Knight(Julia A),Tollenaar(Rob A E M),Beckmann(Matthias W),Ziogas(Argyrios),Christiaens(Marie-Rose),Collée(Johanna Margriet),Reed(Malcolm W R),Severi(Gianluca),Marme(Frederik),Margolin(Sara),Olson(Janet E),Kosma(Veli-Matti),Kristensen(Vessela N),Miron(Alexander),Bogdanova(Natalia),Shah(Mitul),Blomqvist(Carl),Broeks(Annegien),Sherman(Mark),Phillips(Kelly-Anne),Li(Jingmei),Liu(Jianjun),Glendon(Gord),Seynaeve(Caroline),Ekici(Arif B),Leunen(Karin),Kriege(Mieke),Cross(Simon S),Baglietto(Laura),Sohn(Christof),Wang(Xianshu),Kataja(Vesa),Børresen-Dale(Anne-Lise),Meyer(Andreas),Easton(Douglas F),Schmidt(Marjanka K),Bojesen(Stig E)
状态:: 发布时间2012-12-11 , 更新时间 2016-11-22
期刊:: J Clin Oncol
摘要:: We tested the hypotheses that CHEK2*1100delC heterozygosity is associated with increased risk of early death, breast cancer-specific death, and risk of a second breast cancer in women with a first breast cancer.,From 22 studies participating in the Breast Cancer Association Consortium, 25,571 white women with invasive breast cancer were genotyped for CHEK2*1100delC and observed for up to 20 years (median, 6.6 years). We examined risk of early death and breast cancer-specific death by estrogen receptor status and risk of a second breast cancer after a first breast cancer in prospective studies.,CHEK2*1100delC heterozygosity was found in 459 patients (1.8%). In women with estrogen receptor-positive breast cancer, multifactorially adjusted hazard ratios for heterozygotes versus noncarriers were 1.43 (95% CI, 1.12 to 1.82; log-rank P = .004) for early death and 1.63 (95% CI, 1.24 to 2.15; log-rank P < .001) for breast cancer-specific death. In all women, hazard ratio for a second breast cancer was 2.77 (95% CI, 2.00 to 3.83; log-rank P < .001) increasing to 3.52 (95% CI, 2.35 to 5.27; log-rank P < .001) in women with estrogen receptor-positive first breast cancer only.,Among women with estrogen receptor-positive breast cancer, CHEK2*1100delC heterozygosity was associated with a 1.4-fold risk of early death, a 1.6-fold risk of breast cancer-specific death, and a 3.5-fold risk of a second breast cancer. This is one of the few examples of a genetic factor that influences long-term prognosis being documented in an extensive series of women with breast cancer.
语言:: eng
DOI:

文献库文献相关信息

DataTable pData

联系方式

微信公众号

文献库 文献相关信息

DataTable pData

联系方式

微信公众号

文献库文献相关信息